Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00562965 | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined… | Phase 3 | terminated | Nov 26, 2007 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | Phase 2 | terminated | Mar 27, 2012 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01332617 | Phase II Study of Simvastatin for Relapsed/Refractory Myeloma | Phase 2 | withdrawn | Apr 11, 2011 | University of Louisville | Investigators no longer interested in activating study | Other (stated, no rule matched) |
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and… | Phase 1 / Phase 2 | terminated | Aug 24, 2009 | Masonic Cancer Center, University of Minnesota | Lack of efficacy after interim analysis | Efficacy / futility |
| NCT02875002 | Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive… | Phase 1 | withdrawn | Aug 22, 2016 | Yale University | not stated | Not stated |
| NCT03100877 | Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating… | Phase 1 / Phase 2 | withdrawn | Apr 4, 2017 | City of Hope Medical Center | Feasibility Issues | Other (stated, no rule matched) |
| NCT00772668 | Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL… | N/A | terminated | Oct 15, 2008 | University of Miami | Funding | Funding |
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large…(ABC-102) | Phase 1 / Phase 2 | withdrawn | Sep 3, 2014 | RedHill Biopharma Limited | Study was discontinued due to lack of recruitment. | Enrollment / accrual |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | Phase 2 | terminated | Apr 28, 2011 | Masonic Cancer Center, University of Minnesota | not stated | Not stated |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in… | Phase 1 / Phase 2 | withdrawn | Jul 15, 2010 | Masonic Cancer Center, University of Minnesota | Replaced by a new study | Other (stated, no rule matched) |
| NCT01518465 | Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously… | Phase 2 | terminated | Jan 26, 2012 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT01969565 | Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed… | Phase 2 | terminated | Oct 25, 2013 | Emory University | Logistical reasons | Other (stated, no rule matched) |
| NCT00574080 | UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | Phase 3 | terminated | Dec 14, 2007 | University of Arkansas | low accrual | Enrollment / accrual |
| NCT00657553 | Preemptive Strike With Bortezomib in Multiple Myeloma Patients(2007-77) | Phase 3 | terminated | Apr 14, 2008 | University of Arkansas | Due to poor accrual | Enrollment / accrual |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | Phase 1 / Phase 2 | terminated | Aug 24, 2010 | Stanford University | Business decision by funding source | Funding |
| NCT02700022 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell… | Phase 1 | terminated | Mar 7, 2016 | UNC Lineberger Comprehensive Cancer Center | Lack of funding | Funding |
| NCT02815397 | DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma(DLBCL) | Phase 2 | terminated | Jun 28, 2016 | Rush University Medical Center | Poor accrual | Enrollment / accrual |
| NCT00113919 | UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma… | Phase 1 / Phase 2 | terminated | Jun 13, 2005 | University of Arkansas | Due to poor accrual | Enrollment / accrual |
| NCT01646762 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed… | Phase 2 | terminated | Jul 20, 2012 | Mayo Clinic | Did not pass the Stage 1 interim analysis. | Efficacy / futility |
| NCT02455297 | Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 2 | terminated | May 27, 2015 | Bayer | not stated | Not stated |
| NCT01251172 | RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | Phase 2 | withdrawn | Dec 1, 2010 | National Cancer Institute (NCI) | Lack of Drug Supply | Drug supply |
| NCT02662296 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic… | Phase 2 | withdrawn | Jan 25, 2016 | Fred Hutchinson Cancer Center | Low enrollment | Enrollment / accrual |
| NCT03283046 | Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly… | Phase 1 | withdrawn | Sep 14, 2017 | M.D. Anderson Cancer Center | Similar to another study. | Other (stated, no rule matched) |
| NCT00837174 | Relapsed and/or Refractory Non-Hodgkin Lymphoma Study(COMBOSTAT) | Phase 2 | withdrawn | Feb 5, 2009 | The Methodist Hospital Research Institute | Study never activated/opened as funding source and other support not available. | Funding |
| NCT00849251 | Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and… | Phase 1 / Phase 2 | terminated | Feb 23, 2009 | University of Washington | One of the study drugs is not available. | Other (stated, no rule matched) |
| NCT00857324 | Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple… | Phase 1 / Phase 2 | terminated | Mar 6, 2009 | Tiziana Marangon | The Phase I of the study was completed, but Phase 2 has not been activated | Other (stated, no rule matched) |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic… | Phase 1 / Phase 2 | withdrawn | Feb 9, 2016 | University of Michigan Rogel Cancer Center | FDA has placed all trials involving Pacritinib on Full Clinical Hold | Other (stated, no rule matched) |
| NCT01720043 | Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients | Phase 2 | terminated | Nov 1, 2012 | University of Utah | Slow Accrual | Enrollment / accrual |
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple…(MUKfourteen) | Phase 1 / Phase 2 | withdrawn | Jun 19, 2017 | University of Leeds | Withdrawal of pharma support prior to opening to recruitment | Enrollment / accrual |
| NCT01114256 | FNA Tumor Sampling for CD137 Modulation: A Pilot Study | — | terminated | May 3, 2010 | Stanford University | not stated | Not stated |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the… | Phase 2 / Phase 3 | terminated | Jul 14, 2008 | University of Alabama at Birmingham | Accrual goals could not be met within a timely manner | Enrollment / accrual |
| NCT00837200 | Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies | Phase 2 | terminated | Feb 5, 2009 | Milton S. Hershey Medical Center | PI said to close accrual do to funding | Enrollment / accrual |
| NCT00843310 | Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple… | Phase 2 | terminated | Feb 13, 2009 | NYU Langone Health | Due to slow accrual | Enrollment / accrual |
| NCT02658396 | GO-203-2C + Bortezomib For Relapsed Or Refractory MM | Phase 1 | withdrawn | Jan 18, 2016 | Dana-Farber Cancer Institute | Study was never open due to lack of funding | Funding |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT02408042 | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | Phase 1 / Phase 2 | withdrawn | Apr 3, 2015 | Western Regional Medical Center | not stated | Not stated |
| NCT01251952 | Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation | Phase 1 | terminated | Dec 2, 2010 | Barbara Ann Karmanos Cancer Institute | Drug unavailable | Other (stated, no rule matched) |
| NCT01548573 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | Phase 2 | terminated | Mar 8, 2012 | University of Iowa | Met study stopping rules | Other (stated, no rule matched) |
| NCT01965834 | Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic… | Phase 2 | terminated | Oct 18, 2013 | University of Miami | Lack of adequate accrual. | Enrollment / accrual |
| NCT02619812 | Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning… | Phase 2 | terminated | Dec 2, 2015 | Mayo Clinic | Difficulty recruiting; pill burden and nausea were barriers | Enrollment / accrual |
| NCT01220297 | Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related… | Phase 2 | terminated | Oct 13, 2010 | Stanford University | Low accrual | Enrollment / accrual |
| NCT02951117 | A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants… | Phase 1 | withdrawn | Nov 1, 2016 | AbbVie | No participants enrolled | Enrollment / accrual |
| NCT00985140 | Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides | — | terminated | Sep 28, 2009 | Stanford University | Competing studies | Other (stated, no rule matched) |
| NCT00676806 | A Phase II Study of Umbilical Cord Blood Transplantation | Phase 2 | terminated | May 13, 2008 | Tufts Medical Center | Slow accrual | Enrollment / accrual |
| NCT01018927 | Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in… | — | terminated | Nov 25, 2009 | University of Arkansas | PI does not have time to continue study | Other (stated, no rule matched) |
| NCT01729338 | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | Phase 2 | terminated | Nov 20, 2012 | Duke University | not stated | Not stated |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following… | Phase 2 | terminated | Oct 8, 2014 | St. Jude Children's Research Hospital | Investigator's decision. | Investigator |
| NCT00088881 | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients… | Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00934232 | Busulfan in Multiple Myeloma | Phase 1 | terminated | Jul 8, 2009 | Guido Tricot | PI left the institution | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 9, 2018source: clinicaltrials